Globenewswire·2025-11-18 22:28Core Insights - Class actions have been initiated on behalf of stockholders of Skye Bioscience, Inc. and Perrigo Company plc, with deadlines for lead plaintiff petitions set for January 16, 2026 [1][3][7]. Perrigo Company plc - The class period for Perrigo is from February 27, 2023 to November 4, 2025, during which the company allegedly failed to disclose significant issues in its infant formula business acquired from Nestlé, including underinvestment and manufacturing deficiencies [3][4]. - On November 5, 2025, Perrigo announced disappointing financial results for Q3 2025, leading to a reduction in its fiscal year 2025 outlook primarily due to challenges in the infant formula industry [4]. - Following the announcement, Perrigo's stock price dropped by $5.09, or 25.2%, closing at $15.10 per share [4]. Skye Bioscience, Inc. - The class period for Skye is from November 4, 2024 to October 3, 2025, during which the company allegedly made materially false statements regarding the effectiveness and prospects of its drug nimacimab [7]. - On October 6, 2025, Skye disclosed that the nimacimab monotherapy did not achieve its primary endpoint in a clinical study, resulting in a stock price decline of $2.85, or 60%, closing at $1.90 per share [7].